Obiltoxaximab
| 證據等級: L5 | 預測適應症: 8 個 |
目錄
Obiltoxaximab: From Inhalational Anthrax to Postinfectious Vasculitis
One-Sentence Summary
Obiltoxaximab is a monoclonal antibody that neutralizes Bacillus anthracis protective antigen (PA), originally developed for the treatment and prophylaxis of inhalational anthrax. The TxGNN model predicts it may be effective for Postinfectious Vasculitis, but currently no clinical trials and no literature support this specific direction — the prediction rests on knowledge-graph topological similarity alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Inhalational anthrax (B. anthracis PA-toxin neutralization; not confirmed via formal label data — see Data Gaps) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| US/Taiwan Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity Data Gap). Based on available evidence-pack context, obiltoxaximab is a highly target-specific neutralizing monoclonal antibody directed against B. anthracis protective antigen — its proven efficacy is confined to anthrax toxin-mediated disease.
The model’s own rationale for this candidate is explicit that no known mechanistic link exists: postinfectious vasculitis involves immune-complex-mediated vascular inflammation following a broad range of infections, a pathway unrelated to anthrax toxin neutralization. The high TxGNN score is attributed to knowledge-graph embedding similarity rather than any pharmacological or clinical signal, and no supporting trials or publications were identified.
Given this, the prediction should be treated as a hypothesis-generating signal only, not as evidence of therapeutic potential.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US/Taiwan Market Information
No marketing authorizations are currently on file for this market (0 licenses; market status: 未上市 / Not Marketed).
Safety Considerations
Please refer to the package insert for safety information. TFDA label warnings/contraindications and DDI data are not yet available for this drug (flagged as a Blocking Data Gap — DG001).
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication has no supporting clinical trials or literature, no plausible mechanistic overlap with the drug’s known anthrax-toxin-neutralizing activity, and the drug itself lacks confirmed MOA and safety label data — evidence is insufficient at every level to advance this candidate.
To proceed, the following is needed:
- Confirmed mechanism of action (DrugBank API query) — High severity gap
- TFDA label warnings/contraindications (PDF retrieval and parsing) — Blocking gap, required before any safety pre-screening (S1)
- A mechanistic plausibility study evaluating whether anti-toxin antibodies have any role in immune-complex-mediated vasculitis
- Continued monitoring for emerging trials or literature specific to postinfectious vasculitis before reconsidering this candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.